ATE491453T1 - Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges - Google Patents

Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges

Info

Publication number
ATE491453T1
ATE491453T1 AT03752885T AT03752885T ATE491453T1 AT E491453 T1 ATE491453 T1 AT E491453T1 AT 03752885 T AT03752885 T AT 03752885T AT 03752885 T AT03752885 T AT 03752885T AT E491453 T1 ATE491453 T1 AT E491453T1
Authority
AT
Austria
Prior art keywords
eye
treatment
inflammatory diseases
aminoquinoline compounds
aminoquinoline
Prior art date
Application number
AT03752885T
Other languages
English (en)
Inventor
Rajeev Raut
Original Assignee
Rajeev Raut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rajeev Raut filed Critical Rajeev Raut
Application granted granted Critical
Publication of ATE491453T1 publication Critical patent/ATE491453T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT03752885T 2002-05-17 2003-05-14 Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges ATE491453T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38092602P 2002-05-17 2002-05-17
PCT/IN2003/000189 WO2003097025A2 (en) 2002-05-17 2003-05-14 A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom

Publications (1)

Publication Number Publication Date
ATE491453T1 true ATE491453T1 (de) 2011-01-15

Family

ID=29550039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03752885T ATE491453T1 (de) 2002-05-17 2003-05-14 Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges

Country Status (7)

Country Link
US (1) US7084157B2 (de)
EP (1) EP1558254B1 (de)
AT (1) ATE491453T1 (de)
AU (1) AU2003249575A1 (de)
DE (1) DE60335404D1 (de)
PT (1) PT1558254E (de)
WO (1) WO2003097025A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273366B2 (en) * 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
US20120058993A1 (en) * 2003-07-23 2012-03-08 Douglas Pharmaceuticals Ltd. Stable Suspension Formulation
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
CN1989439B (zh) * 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
JP4239036B2 (ja) * 2005-02-21 2009-03-18 ラウト，ラジーブ 改良薬剤組成物
WO2006108666A1 (en) * 2005-04-13 2006-10-19 Proteosys Ag Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
US9839667B2 (en) * 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
JP2009514969A (ja) * 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2007098047A2 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
US20080125454A1 (en) * 2006-10-05 2008-05-29 Wyeth Methods and Compositions for Treatment of Scleritis and Related Disorders
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
WO2009089399A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
CN108697641A (zh) * 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
WO2018107200A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
AU2017377659A1 (en) * 2016-12-13 2019-07-11 Beta Therapeutics Pty. Ltd. Methods of treating ocular disorders
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN113318231A (zh) * 2020-02-28 2021-08-31 上海医药集团股份有限公司 一种4-氨基喹啉类化合物的应用
CN114796216A (zh) * 2022-01-04 2022-07-29 南京医科大学 甲氟喹在防治全身代谢性炎症疾病中的应用
CN114920694B (zh) * 2022-07-18 2022-11-08 康瑞鑫(天津)药物研究院有限公司 羟氯喹粗品的精制方法及制备的羟氯喹产品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
RO92640A2 (ro) * 1985-05-13 1987-09-30 Institutul De Medicina Si Farmacie,Ro Metoda pentru tratamentul keratitelor virotice
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
CA2133620A1 (en) * 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
DE69614149T2 (de) * 1995-11-16 2002-03-14 F. Hoffmann-La Roche Ag, Basel Chinolinderivate als antimalariamittel
US20020091139A1 (en) * 1997-10-17 2002-07-11 Damon Todd Holdings, L.L.C. Treatment and delivery of hydroxychloroquine
US6384081B2 (en) * 1998-10-09 2002-05-07 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
CA2372443C (en) * 1999-04-30 2010-07-13 Apt Pharmaceuticals, L.L.C. Local administration of anti-malarial agents for the treatment of inflammatory diseases
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
IL161821A0 (en) * 2001-11-09 2005-11-20 Lauren Charous Pharmaceutical compositions containing an aminoquinoline or a hydroxyquinoline derivative

Also Published As

Publication number Publication date
EP1558254B1 (de) 2010-12-15
US7084157B2 (en) 2006-08-01
AU2003249575A8 (en) 2003-12-02
EP1558254A2 (de) 2005-08-03
WO2003097025B1 (en) 2004-03-18
WO2003097025A2 (en) 2003-11-27
US20030216431A1 (en) 2003-11-20
DE60335404D1 (de) 2011-01-27
AU2003249575A1 (en) 2003-12-02
WO2003097025A3 (en) 2004-02-12
PT1558254E (pt) 2011-02-15

Similar Documents

Publication Publication Date Title
ATE491453T1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EA200601239A1 (ru) Замещённые хинолиновые соединения
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
EA200500133A1 (ru) Производные пирролидина в качестве антагонистов окситоцина
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE602008004741D1 (de) Thiophenderivate als medikamente zur behandlung von okularer hypertonie
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors
DE602004014115D1 (de) Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure
ATE369849T1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties